{Reference Type}: Journal Article
{Title}: Metabolic and cardiovascular risks of hormone treatment for transgender individuals.
{Author}: de Silva NL;Dimakopoulou A;Quinton O;Jayasena CN;
{Journal}: Best Pract Res Clin Endocrinol Metab
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 26
{Factor}: 5.667
{DOI}: 10.1016/j.beem.2024.101907
{Abstract}: Identifying metabolic and cardiovascular risks of gender-affirming hormone therapy (GAHT) is challenging due to other confounding variables that affect patient outcomes and the diversity of treatment regimes. Masculinising hormone therapy produces atherogenic lipid profiles, while effects on other metabolic parameters are not consistent. There is insufficient evidence to conclude if cardiovascular disease risk among transmen is increased. The effects of feminising hormone therapy on metabolic parameters do not demonstrate a consistent pattern in the available literature. However, the risk of venous thromboembolism is greater in transwomen than in cis-gender men and women with a possible increase in cardiovascular disease risk. It is recommended to discuss the potential effects of GAHT on cardiovascular health and encourage patients seeking GAHT to adopt a healthy lifestyle. Performing baseline and periodic assessments of cardiovascular risk factors would enable early identification and interventions. In high-risk individuals, the cardiovascular effects of hormonal regimes might impact the treatment decision.